Association of cerebrospinal fluid neurofilament light concentration with Alzheimer disease progression

JAMA Neurology

Volumn 73, Issue 1, 2016, Pages 60-67

  Zetterberg, Henrik ^a,b   Skillbäck, Tobias ^a   Mattsson, Niklas ^c,d,e   Trojanowski, John Q ^f   Portelius, Erik ^a   Shaw, Leslie M ^f   Weiner, Michael W ^c   Blennow, Kaj ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e LUND UNIVERSITY   (Sweden)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROFILAMENT LIGHT PROTEIN; NEUROFILAMENT PROTEIN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; NEUROFILAMENT PROTEIN L;

ADULT; AGED; ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE; ARTICLE; BRAIN ATROPHY; BRAIN SIZE; CEREBROSPINAL FLUID ANALYSIS; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HIPPOCAMPUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NEUROIMAGING; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN DETERMINATION; WHITE MATTER; CEREBROSPINAL FLUID; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BIOMARKERS; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MILD COGNITIVE IMPAIRMENT; NEUROFILAMENT PROTEINS;

EID: 84954224391     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2015.3037     Document Type: Article

References (31)

1. Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet. 2006;368(9533): 387-403.
2. Delbeuck X, Van der Linden M, Collette F. Alzheimer's disease as a disconnection syndrome? Neuropsychol Rev. 2003;13(2): 79-92.
3. Brun A, Englund E. A white matter disorder in dementia of the Alzheimer type: A pathoanatomical study. Ann Neurol. 1986;19(3): 253-262.
4. Sjobeck M, Haglund M, Englund E. Decreasing myelin density reflected increasing white matter pathology in Alzheimer's disease: A neuropathological study. Int J Geriatr Psychiatry. 2005;20(10): 919-926.
5. Hua X, Lee S, Hibar DP, et al; Alzheimer's Disease Neuroimaging Initiative. Mapping Alzheimer's disease progression in 1309 MRI scans: Power estimates for different inter-scan intervals. Neuroimage. 2010;51(1): 63-75.
6. Hua X, Leow AD, Lee S, et al; Alzheimer's Disease Neuroimaging Initiative. 3D characterization of brain atrophy in Alzheimer's disease and mild cognitive impairment using tensor-based morphometry. Neuroimage. 2008;41 (1): 19-34.
7. Hua K, Zhang J,Wakana S, et al. Tract probability maps in stereotaxic spaces: Analyses of white matter anatomy and tract-specific quantification. Neuroimage. 2008;39(1): 336-347.
8. Migliaccio R, Agosta F, Possin KL, Rabinovici GD, Miller BL, Gorno-Tempini ML. White matter atrophy in Alzheimer's disease variants. Alzheimers Dement. 2012;8(5)(suppl): S78-87.e1, 2. doi: 10.1016/j.jalz.2012 .04.010.
9. Liu Y, Spulber G, Lehtimaki KK, et al. Diffusion tensor imaging and tract-based spatial statistics in Alzheimer's disease and mild cognitive impairment. Neurobiol Aging. 2011;32(9): 1558-1571.
10. Medina D, DeToledo-Morrell L, Urresta F, et al. White matter changes inmild cognitive impairment and AD: A diffusion tensor imaging study. Neurobiol Aging. 2006;27(5): 663-672.
11. Rose SE, Chen F, Chalk JB, et al. Loss of connectivity in Alzheimer's disease: An evaluation of white matter tract integrity with colour coded MR diffusion tensor imaging. J Neurol Neurosurg Psychiatry. 2000;69(4): 528-530.
12. Stebbins GT, Murphy CM. Diffusion tensor imaging in Alzheimer's disease and mild cognitive impairment. Behav Neurol. 2009;21(1): 39-49.
13. Trojanowski JQ,Walkenstein N, Lee VM. Expression of neurofilament subunits in neurons of the central and peripheral nervous system: An immunohistochemical study with monoclonal antibodies. J Neurosci. 1986;6(3): 650-660.
14. Lee MK, Xu Z,Wong PC, Cleveland DW. Neurofilaments are obligate heteropolymers in vivo. J Cell Biol. 1993;122(6): 1337-1350.
15. Teunissen CE, Khalil M. Neurofilaments as biomarkers in multiple sclerosis. Mult Scler. 2012;18 (5): 552-556.
16. Sjogren M, BlombergM, Jonsson M, et al. Neurofilament protein in cerebrospinal fluid: A marker of white matter changes. J Neurosci Res. 2001;66(3): 510-516.
17. Sjogren M, Rosengren L, Minthon L, Davidsson P, Blennow K,Wallin A. Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD. Neurology. 2000;54(10): 1960-1964.
18. Pijnenburg YA, Janssen JC, Schoonenboom NS, et al. CSF neurofilaments in frontotemporal dementia compared with early onset Alzheimer's disease and controls. Dement Geriatr Cogn Disord. 2007;23(4): 225-230.
19. LandqvistWaldoM, Frizell Santillo A, Passant U, et al. Cerebrospinal fluid neurofilament light chain protein levels in subtypes of frontotemporal dementia. BMC Neurol. 2013;13: 54.
20. Skillback T, Farahmand B, Bartlett JW, et al. CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival. Neurology. 2014;83(21): 1945-1953.
21. Jeppsson A, Zetterberg H, Blennow K,Wikkelso C. Idiopathic normal-pressure hydrocephalus: Pathophysiology and diagnosis by CSF biomarkers. Neurology. 2013;80(15): 1385-1392.
22. Zetterberg H, Jacobsson J, Rosengren L, Blennow K, Andersen PM. Cerebrospinal fluid neurofilament light levels in amyotrophic lateral sclerosis: Impact of SOD1 genotype. Eur J Neurol. 2007;14(12): 1329-1333.
23. Shahim P, Darin N, Andreasson U, et al. Cerebrospinal fluid brain injury biomarkers in children: A multicenter study. Pediatr Neurol. 2013; 49(1): 31-39.e2. doi: 10.1016/j.pediatrneurol.2013.02 .015.
24. Mattsson N, Bremell D, Anckarsater R, et al. Neuroinflammation in Lyme neuroborreliosis affects amyloid metabolism. BMC Neurol. 2010; 10: 51.
25. Hagberg L, Fuchs D, Rosengren L, Gisslen M. Intrathecal immune activation is associated with cerebrospinal fluid markers of neuronal destruction in AIDS patients. J Neuroimmunol. 2000;102(1): 51-55.
26. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al; Alzheimer's Disease Neuroimaging Initiative. Cerebrospinal fluid biomarker signature in Alzheimer's Disease Neuroimaging Initiative subjects. Ann Neurol. 2009;65(4): 403-413.
27. Jack CR Jr, Bernstein MA, Fox NC, et al. The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging. 2008;27(4): 685-691.
28. Fischl B, Salat DH, Busa E, et al. Whole brain segmentation: Automated labeling of neuroanatomical structures in the human brain. Neuron. 2002;33(3): 341-355.
29. Fischl B, van der Kouwe A, Destrieux C, et al. Automatically parcellating the human cerebral cortex. Cereb Cortex. 2004;14(1): 11-22.
30. Fortea J, Vilaplana E, Alcolea D, et al; Alzheimer's Disease Neuroimaging Initiative. Cerebrospinal fluid ß-amyloid and phospho-tau biomarker interactions affecting brain structure in preclinical Alzheimer disease. Ann Neurol. 2014;76 (2): 223-230.
31. Scherling CS, Hall T, Berisha F, et al. Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration. Ann Neurol. 2014;75(1): 116-126.